Abstract Number: 1432 • ACR Convergence 2024
Diagnostic Performance of Mayor Salivary Gland Ultrasound for Diagnosis of Sjögren’s Syndrome in Routine Clinical Practice
Background/Purpose: Major salivary glands ultrasound (SGU) is a promising tool in the diagnosis of Sjögren syndrome (SS) and has demonstrated good sensitivity and specificity in…Abstract Number: 2293 • ACR Convergence 2024
Altered Expression of the MicroRNA Biogenesis Machinery Components Correlates with Inflammatory Parameters in Salivary Glands of Patient with Sjögren’s Disease
Background/Purpose: MicroRNAs (miRNAs) are small non-coding RNAs involved in the regulation of gene expression at the post-transcriptional level (by translational blocking or mRNA degradation). The…Abstract Number: 2309 • ACR Convergence 2024
Damage Accrual Predicts the Development of Lymphoma in Primary Sjogren’s Syndrome
Background/Purpose: Primary Sjogren Syndrome (pSS) is an autoimmune disease affecting primarily exocrine glands. Over a quarter of patients have systemic involvement, which includes the development…Abstract Number: 0889 • ACR Convergence 2024
Unraveling the Progression of Sjögren’s Disease at the Cellular and Histological Level Using Single-cell and Spatial Transcriptomics
Background/Purpose: Sjögren’s Disease (SjD) is a systemic autoimmune disease that primarily targets salivary and lacrimal glands, causing tissue deterioration and loss of function. Disease progression…Abstract Number: 1416 • ACR Convergence 2024
Ultrasound (US)-guided Core-needle Biopsy (CNB) of the Non-swollen Parotid Gland: A Feasible and Well-tolerated Technique for Diagnosing and Stratifying Sjögren’s Disease (SjD)
Background/Purpose: Histopathology remains a cornerstone in the diagnostic workup of Sjögren’s disease (SjD). Ultrasound (US)-guided core needle biopsy (CNB) of the parotid gland has emerged…Abstract Number: 1652 • ACR Convergence 2024
Extracellular Vesicles from Lymphocyte B and Neutrophil Presents Ro52, Ro60 and La Autoantigens in Patient Suffering from Sjögren Syndrome
Background/Purpose: Extracellular Vesicles (EVs) are double lipid bilayer-enclosed membranous vesicles, produced and discharged from almost all cells. EVs are known for inter-cellular communication by releasing…Abstract Number: 2294 • ACR Convergence 2024
Pharmacodynamic Effects of Nipocalimab on Disease Biomarkers in Patients with Moderate-to-Severe Active Sjögren’s Disease: Results from a Multicenter, Randomized, Double-blinded, Placebo-controlled Phase 2 Study
Background/Purpose: Nipocalimab is a fully human, immunoglobulin G (IgG) 1 monoclonal antibody that selectively binds to the IgG-binding site of the neonatal crystallizable fragment receptor…Abstract Number: 2310 • ACR Convergence 2024
Prospective Evaluation of Pulmonary Involvement in Patients with Primary Sjögren’s Disease, Using Pulmonary Function Tests and High Resolution Computed Tomography, Reveals High Prevalence of Subclinical Interstitial Lung Disease, Along with Small Airways Disease
Background/Purpose: Interstitial lung disease (ILD) and small airways disease (SAD) are frequent pulmonary manifestations of primary Sjögren’s disease (SjD). The relation between these two entities…Abstract Number: L10 • ACR Convergence 2023
Dazodalibep, a CD40L Antagonist, in a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Crossover Trial of Subjects with Sjögren’s Disease Having Unacceptable Symptomatic Burden but Limited Extraglandular Organ Involvement
Background/Purpose: Dazodalibep (DAZ) is a non-antibody fusion protein that acts as a CD40L antagonist and blocks costimulatory signals between immune cells, including T cells, B…Abstract Number: L18 • ACR Convergence 2023
Immune-metabolic Heterogeneity and Clinical Implications in Primary Sjogren’s Syndrome Revealed by Molecular Classification of Salivary Glands
Background/Purpose: Primary Sjögren's syndrome (pSS) is a complex autoimmune disease with significant heterogeneity. Our study aimed to clarify the etiology and molecular variation of the…Abstract Number: 0802 • ACR Convergence 2023
Targeting Fibroblasts in Inflammatory Disease Using Engineered T Cells
Background/Purpose: Fibroblast activation protein alpha (FAPa) expressing fibroblasts orchestrate tissue inflammation and damage in rheumatoid arthritis (RA) as well as tissue immunity in primary Sjögren's…Abstract Number: 1374 • ACR Convergence 2023
Interstitial Lung Disease Is Frequent in Primary Sjögren’s Syndrome and Is Associated with Reduced Survival
Background/Purpose: Interstitial lung disease (ILD) has been reported to be present in 10-15% of patients with primary Sjögren's syndrome (pSS). Knowledge on risk factors predicting…Abstract Number: 1771 • ACR Convergence 2023
Role of Periostin in the Pathophysiology and Accurate Diagnosis of Interstitial Lung Disease Associated with Autoimmune Diseases
Background/Purpose: Periostin is an extracellular matrix protein that contributes to the development and repair of lung tissue [1]. Previous works have described periostin as a…Abstract Number: 2191 • ACR Convergence 2023
Efficacy of anti-CD38 Treatment with Daratumumab in Two Cases of Refractory and Severe Sjogren Disease
Background/Purpose: Sjögren's disease (Sjo) is a systemic autoimmune disease. In 80% of the patients, Sjo is responsible for dryness, fatigue, and joint pain. In 10%…Abstract Number: 1219 • ACR Convergence 2023
Patient Experience of Brain Fog to Inform the Development of a De Novo Patient Reported Outcome (PRO) in Patients with Sjögren’s Disease
Background/Purpose: Brain fog is commonly reported by SJD patients, though limited evidence exists to understand patient experiences. Various terms may be used to describe brain…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 18
- Next Page »